Methods for reducing or suppressing the adverse effectiveness of l-dopa and / or dopamine agonist therapy, and for moderate l-dopa treatment, composition for moderate l-dopa treatment, method for treating parkinson's disease and / or complications. -dopa motors, composition for the treatment of parkinson's disease, and methods for prolonging the effective treatment of parkinson's disease, and for treating movement disorders

摘要

"METHODS FOR REDUCING OR SUPPRESSING THE ADVERSE EFFECTIVENESS OF L-DOPA THERAPY AND / OR DOPAMINE AGONIST, AND FOR MODERATE L-DOPA TREATMENT, COMPOSITION FOR MODERATE L-DOPA TREATMENT OR METHOD L-DOPA MOTOR COMPLICATIONS, COMPOSITION FOR THE TREATMENT OF PARKINSON'S DISEASE, AND METHODS TO EXTEND EFFECTIVE TREATMENT OF PARKINSON'S DISEASE, AND TO TREAT MOVEMENT DISORDERS ". The present invention relates to methods of treating movement disorders by administering an effective amount of one or more A 2A 2 adenosine receptor antagonists to a patient in need of such treatment. The present invention also provides methods for reducing the adverse effects of L-DOPA in patients receiving L-DOPA therapy in the treatment of Parkinson's disease. The present invention further provides methods and compositions for treating patients with Parkinson's disease with subclinically effective doses of L-DOPA by combining treatment of L-DOPA with an effective amount of one or more A2A adenosine receptor antagonists (i.e. , a moderate effect of L-DOPA). The present invention further provides methods of effective treatment of Parkinson's disease by co-administering at least one A2A adenosine receptor antagonist, L-DOPA and a dopamine agonist and / or a COMT inhibitor and / or an MAO inhibitor. The present invention further provides methods of prolonging the effective treatment of Parkinson's disease by administering an A 2A-adenosine receptor antagonist alone or together with a dopamine agonist, and / or a COMT inhibitor, and / or an inhibitor. of MAO without prior or subsequent administration of L-DOPA, delaying the onset of motor complication of L-DOPA.